Results 21 to 30 of about 25,216 (236)

Single domain based bispecific antibody, Muc1-Bi-1, and its humanized form, Muc1-Bi-2, induce potent cancer cell killing in muc1 positive tumor cells. [PDF]

PLoS ONE, 2018
Muc1 is one of the most studied tumor antigens. However, antibodies or antibody-toxin conjugates against Muc1 have not shown significant efficacy for tumors with Muc1 overexpression.
Yumei Li, Changhua Zhou, Jing Li, Jiayu Liu, Limin Lin, Li Li, Donglin Cao, Qing Li, Zhong Wang   +8 more
doaj   +1 more source

Bispecific antibody CAP256.J3LS targets V2-apex and CD4-binding sites with high breadth and potency

mAbs, 2023
Antibody CAP256-VRC26.25 targets the second hypervariable region (V2) at the apex of the HIV envelope (Env) trimer with extraordinary neutralization potency, although less than optimal breadth. To improve breadth, we linked the light chain of CAP256V2LS,
Baoshan Zhang, Jason Gorman, Young D. Kwon, Amarendra Pegu, Cara W. Chao, Tracy Liu, Mangaiarkarasi Asokan, Michael F. Bender, Tatsiana Bylund, Leland Damron, Deepika Gollapudi, Paula Lei, Yile Li, Cuiping Liu, Mark K. Louder, Krisha McKee, Adam S. Olia, Reda Rawi, Arne Schön, Shuishu Wang, Eun Sung Yang, Yongping Yang, Kevin Carlton, Nicole A. Doria-Rose, Lawrence Shapiro, Michael S. Seaman, John R. Mascola, Peter D. Kwong   +27 more
doaj   +1 more source

A new approach to produce IgG4-like bispecific antibodies

Scientific Reports, 2021
While achieving rapid developments in recent years, bispecific antibodies are still difficult to design and manufacture, due to mispair of both heavy and light chains. Here we report a novel technology to make bispecific molecules.
Caizhi Zhao, Wei Zhang, Guihua Gong, Liping Xie, Ming-Wei Wang, Youjia Hu   +5 more
doaj   +1 more source

A Bispecific Antibody That Simultaneously Recognizes the V2- and V3-Glycan Epitopes of the HIV-1 Envelope Glycoprotein Is Broader and More Potent than Its Parental Antibodies

mBio, 2020
Broadly neutralizing antibodies (bNAbs) can prevent and control an HIV-1 infection, but their breadth is invariably too limited for use as monotherapy. To address this problem, bi- and trispecific antibody-like constructs have been developed.
Meredith E. Davis-Gardner, Barnett Alfant, Jesse A. Weber, Matthew R. Gardner, Michael Farzan   +4 more
doaj   +1 more source

Bispecific antibodies

Drug Discovery Today, 2015
Bispecific antibodies have emerged as molecules with a multitude of ...
Kontermann, Roland E., Brinkmann, Ulrich
openaire   +3 more sources

Design and Production of Bispecific Antibodies

Antibodies, 2019
With the current biotherapeutic market dominated by antibody molecules, bispecific antibodies represent a key component of the next-generation of antibody therapy.
Qiong Wang, Yiqun Chen, Jaeyoung Park, Xiao Liu, Yifeng Hu, Tiexin Wang, Kevin McFarland, Michael J. Betenbaugh   +7 more
doaj   +1 more source

Effective clearance of rituximab-resistant tumor cells by breaking the mirror-symmetry of immunoglobulin G and simultaneous binding to CD55 and CD20

Scientific Reports, 2023
Complement-dependent cytotoxicity (CDC), which eliminates aberrant target cells through the assembly and complex formation of serum complement molecules, is one of the major effector functions of anticancer therapeutic antibodies.
Sang Min Lee, Sung-Won Min, Hyeong Sun Kwon, Gong-Deuk Bae, Ji Hae Jung, Hye In Park, Seung Hyeon Lee, Chung Su Lim, Byoung Joon Ko, Ji Chul Lee, Sang Taek Jung   +10 more
doaj   +1 more source

Common light chain chickens produce human antibodies of high affinity and broad epitope coverage for the engineering of bispecifics

mAbs, 2021
Bispecific antibodies are an important and growing segment in antibody therapeutics, particularly in the immuno-oncology space. Manufacturing of a bispecific antibody with two different heavy chains is greatly simplified if the light chains can be the ...
Kathryn H. Ching, Kimberley Berg, Kevin Reynolds, Darlene Pedersen, Alba Macias, Yasmina N. Abdiche, William D. Harriman, Philip A. Leighton   +7 more
doaj   +1 more source

BiTEs, DARTS, BiKEs and TriKEs—Are Antibody Based Therapies Changing the Future Treatment of AML?

Life, 2021
Nearly four decades after their conceptualization, antibody-based therapies are slowly being added to the treatment landscape of acute myeloid leukemia (AML). While the antibody–drug conjugate gemtuzumab ozogamicin is the only antibody-based therapy that
Cecily Allen, Amer M. Zeidan, Jan Philipp Bewersdorf   +2 more
doaj   +1 more source

Emerging Antibodies in Cancer Therapy

Advanced NanoBiomed Research, 2023
Since the first monoclonal antibody, Orthoclone OKT3, was approved in 1986 for the treatment of acute allograft rejection in renal transplant recipients, the number of antibody‐based therapies has increased remarkably, with more than 130 monoclonal ...
Yaping Sun, Jian Xu
doaj   +1 more source